{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:20:18Z","timestamp":1792030818730,"version":"4.4.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,24]]},"DOI":"10.7759\/cureus.72252","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T07:59:51Z","timestamp":1729756791000},"source":"Crossref","is-referenced-by-count":3,"title":["N-acetylcysteine Clinical Applications"],"prefix":"10.7759","author":[{"given":"Zoubaida","family":"Yahia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Yahia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-5223(19)32956-3","article-title":"Clinical evaluation of a new mucolytic agent, acetyl-cysteine","volume":"44","author":"Webb W","year":"1962","unstructured":"Webb W. Clinical evaluation of a new mucolytic agent, acetyl-cysteine. J Thorac Cardiovasc Surg. 1962, 44:330-43.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000195085","article-title":"Acetylcysteine: a drug with an interesting past and a fascinating future","volume":"50 Suppl 1","author":"Ziment I","year":"1986","unstructured":"Ziment I. Acetylcysteine: a drug with an interesting past and a fascinating future. Respiration. 1986, 50 Suppl 1:26-30. 10.1159\/000195085","journal-title":"Respiration"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/copd.2006.1.4.425","article-title":"Role of N-acetylcysteine in the management of COPD","volume":"1","author":"Sadowska AM","year":"2006","unstructured":"Sadowska AM, Verbraecken J, Darquennes K, De Backer WA. Role of N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis. 2006, 1:425-34. 10.2147\/copd.2006.1.4.425","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref4","article-title":"Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers","volume":"11","author":"Van Schooten F","year":"2002","unstructured":"Van Schooten F, Besarati Nia A, De Flora S, et al.. Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers. Cancer Epidemiol Biomarkers Prev. 2002, 11:167-75.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s000180300001","article-title":"Molecular mechanisms of N-acetylcysteine actions","volume":"60","author":"Zafarullah M","year":"2003","unstructured":"Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci. 2003, 60:6-20. 10.1007\/s000180300001","journal-title":"Cell Mol Life Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1278316","article-title":"The antihypertensive effect of cysteine","volume":"18","author":"Vasdev S","year":"2009","unstructured":"Vasdev S, Singal P, Gill V. The antihypertensive effect of cysteine. Int J Angiol. 2009, 18:7-21. 10.1055\/s-0031-1278316","journal-title":"Int J Angiol"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.1021\/jf040266f","article-title":"Biologically important thiols in various vegetables and fruits","volume":"52","author":"Demirkol O","year":"2004","unstructured":"Demirkol O, Adams C, Ercal N. Biologically important thiols in various vegetables and fruits. J Agric Food Chem. 2004, 52:8151-4.","journal-title":"J Agric Food Chem"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107916","article-title":"The mechanism of action of N-acetylcysteine (NAC): The emerging role of H(2)S and sulfane sulfur species","volume":"228","author":"Pedre B","year":"2021","unstructured":"Pedre B, Barayeu U, Ezeri\u0146a D, Dick TP. The mechanism of action of N-acetylcysteine (NAC): The emerging role of H(2)S and sulfane sulfur species. Pharmacol Ther. 2021, 228:107916. 10.1016\/j.pharmthera.2021.107916","journal-title":"Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.17.1.59","article-title":"Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature","volume":"17","author":"Ebell MH","year":"2004","unstructured":"Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B, Bowman M. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract. 2004, 17:59-67. 10.3122\/jabfm.17.1.59","journal-title":"J Am Board Fam Pract"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1245125","article-title":"What is oxidative stress? [Article in German]","volume":"227","author":"Augustin AJ","year":"2010","unstructured":"Augustin AJ. What is oxidative stress? [Article in German]. Klin Monbl Augenheilkd. 2010, 227:90-8. 10.1055\/s-0029-1245125","journal-title":"Klin Monbl Augenheilkd"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5174957","article-title":"N-acetyl-L-cysteine protects human retinal pigment epithelial cells from oxidative damage: implications for age-related macular degeneration","volume":"2019","author":"Terluk MR","year":"2019","unstructured":"Terluk MR, Ebeling MC, Fisher CR, et al.. N-acetyl-L-cysteine protects human retinal pigment epithelial cells from oxidative damage: implications for age-related macular degeneration. Oxid Med Cell Longev. 2019, 2019:5174957. 10.1155\/2019\/5174957","journal-title":"Oxid Med Cell Longev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2011.01.036","article-title":"N-acetylcysteine amide (NACA) prevents retinal degeneration by up-regulating reduced glutathione production and reversing lipid peroxidation","volume":"178","author":"Schimel AM","year":"2011","unstructured":"Schimel AM, Abraham L, Cox D, et al.. N-acetylcysteine amide (NACA) prevents retinal degeneration by up-regulating reduced glutathione production and reversing lipid peroxidation. Am J Pathol. 2011, 178:2032-43. 10.1016\/j.ajpath.2011.01.036","journal-title":"Am J Pathol"},{"key":"ref13","article-title":"A double- blind, cross-over, study of oral N-acetylcysteine in Sjo\u0308gren\u2019s syndrome","volume":"61","author":"Walters MT","year":"1986","unstructured":"Walters MT, Rubin CE, Keightley SJ, et al.. A double- blind, cross-over, study of oral N-acetylcysteine in Sjo\u0308gren\u2019s syndrome. Scand J Rheumatol Suppl. 1986, 61:253-8.","journal-title":"Scand J Rheumatol Suppl"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2010.0001","article-title":"Efficacy of topical N-acetylcysteine in the treatment of meibomian gland dysfunction","volume":"26","author":"Akyol-Salman I","year":"2010","unstructured":"Akyol-Salman I, Azizi S, Mumcu U, Baykal O. Efficacy of topical N-acetylcysteine in the treatment of meibomian gland dysfunction. J Ocul Pharmacol Ther. 2010, 26:329-33. 10.1089\/jop.2010.0001","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s0891-5849(02)01109-7","article-title":"Effect of high-glucose levels on protein oxidation in cultured lens cells, and in crystalline and albumin solution and its inhibition by vitamin B6 and N-acetylcysteine: its possible relevance to cataract formation in diabetes","volume":"33","author":"Jain AK","year":"2002","unstructured":"Jain AK, Lim G, Langford M, Jain SK. Effect of high-glucose levels on protein oxidation in cultured lens cells, and in crystalline and albumin solution and its inhibition by vitamin B6 and N-acetylcysteine: its possible relevance to cataract formation in diabetes. Free Radic Biol Med. 2002, 33:1615-21. 10.1016\/s0891-5849(02)01109-7","journal-title":"Free Radic Biol Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.15.7923","article-title":"Growth retardation and cysteine deficiency in gamma-glutamyl transpeptidase-deficient mice","volume":"93","author":"Lieberman MW","year":"1996","unstructured":"Lieberman MW, Wiseman AL, Shi ZZ, et al.. Growth retardation and cysteine deficiency in gamma-glutamyl transpeptidase-deficient mice. Proc Natl Acad Sci U S A. 1996, 93:7923-6. 10.1073\/pnas.93.15.7923","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e31819c46b1","article-title":"Retinal oxidative stress induced by intraocular hypertension in rats may be ameliorated by brimonidine treatment and N-acetyl cysteine supplementation","volume":"18","author":"Ozdemir G","year":"2009","unstructured":"Ozdemir G, Tolun FI, Gul M, Imrek S. Retinal oxidative stress induced by intraocular hypertension in rats may be ameliorated by brimonidine treatment and N-acetyl cysteine supplementation. J Glaucoma. 2009, 18:662-5. 10.1097\/IJG.0b013e31819c46b1","journal-title":"J Glaucoma"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1365-z","article-title":"Differential effects of N-acetylcysteine on retinal degeneration in two mouse models of normal tension glaucoma","volume":"10","author":"Sano H","year":"2019","unstructured":"Sano H, Namekata K, Kimura A, et al.. Differential effects of N-acetylcysteine on retinal degeneration in two mouse models of normal tension glaucoma. Cell Death Dis. 2019, 10:75. 10.1038\/s41419-019-1365-z","journal-title":"Cell Death Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2015.04.015","article-title":"Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review","volume":"55","author":"Deepmala","year":"2015","unstructured":"Deepmala, Slattery J, Kumar N, et al.. Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neurosci Biobehav Rev. 2015, 55:294-321. 10.1016\/j.neubiorev.2015.04.015","journal-title":"Neurosci Biobehav Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23123305","article-title":"Overview on the effects of N-acetylcysteine in neurodegenerative diseases","volume":"23","author":"Tardiolo G","year":"2018","unstructured":"Tardiolo G, Bramanti P, Mazzon E. Overview on the effects of N-acetylcysteine in neurodegenerative diseases. Molecules. 2018, 23:10.3390\/molecules23123305","journal-title":"Molecules"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3233\/jad-2005-7206","article-title":"N-acteyl cysteine alleviates oxidative damage to central nervous system of ApoE-deficient mice following folate and vitamin E-deficiency","volume":"7","author":"Tchantchou F","year":"2005","unstructured":"Tchantchou F, Graves M, Rogers E, Ortiz D, Shea TB. N-acteyl cysteine alleviates oxidative damage to central nervous system of ApoE-deficient mice following folate and vitamin E-deficiency. J Alzheimers Dis. 2005, 7:135-8; discussion 173-80. 10.3233\/jad-2005-7206","journal-title":"J Alzheimers Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2174\/1567205053585855","article-title":"Pilot study of the reducing effect on amyloidosis in vivo by three FDA pre-approved drugs via the Alzheimer's APP 5' untranslated region","volume":"2","author":"Tucker S","year":"2005","unstructured":"Tucker S, Ahl M, Bush A, Westaway D, Huang X, Rogers JT. Pilot study of the reducing effect on amyloidosis in vivo by three FDA pre-approved drugs via the Alzheimer's APP 5' untranslated region. Curr Alzheimer Res. 2005, 2:249-54. 10.2174\/1567205053585855","journal-title":"Curr Alzheimer Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.57.8.1515","article-title":"Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease","volume":"57","author":"Adair JC","year":"2001","unstructured":"Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology. 2001, 57:1515-7. 10.1212\/wnl.57.8.1515","journal-title":"Neurology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1996.0136","article-title":"Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease","volume":"141","author":"Offen D","year":"1996","unstructured":"Offen D, Ziv I, Sternin H, Melamed E, Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp Neurol. 1996, 141:32-9. 10.1006\/exnr.1996.0136","journal-title":"Exp Neurol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1548","article-title":"N-acetyl cysteine is associated with dopaminergic improvement in Parkinson's disease","volume":"106","author":"Monti DA","year":"2019","unstructured":"Monti DA, Zabrecky G, Kremens D, et al.. N-acetyl cysteine is associated with dopaminergic improvement in Parkinson's disease. Clin Pharmacol Ther. 2019, 106:884-90. 10.1002\/cpt.1548","journal-title":"Clin Pharmacol Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/0165-5728(94)90212-7","article-title":"Oral administration of the oxidant-scavenger N-acetyl-L-cysteine inhibits acute experimental autoimmune encephalomyelitis","volume":"50","author":"Lehmann D","year":"1994","unstructured":"Lehmann D, Karussis D, Misrachi-Koll R, Shezen E, Ovadia H, Abramsky O. Oral administration of the oxidant-scavenger N-acetyl-L-cysteine inhibits acute experimental autoimmune encephalomyelitis. J Neuroimmunol. 1994, 50:35-42. 10.1016\/0165-5728(94)90212-7","journal-title":"J Neuroimmunol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/1740-2557-2-4","article-title":"N-acetyl-L-cysteine ameliorates the inflammatory disease process in experimental autoimmune encephalomyelitis in Lewis rats","volume":"2","author":"Stanislaus R","year":"2005","unstructured":"Stanislaus R, Gilg AG, Singh AK, Singh I. N-acetyl-L-cysteine ameliorates the inflammatory disease process in experimental autoimmune encephalomyelitis in Lewis rats. J Autoimmune Dis. 2005, 2:4. 10.1186\/1740-2557-2-4","journal-title":"J Autoimmune Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.118.021755","article-title":"Protective effects of brain infarction by N-acetylcysteine derivatives","volume":"49","author":"Uemura T","year":"2018","unstructured":"Uemura T, Watanabe K, Ko K, et al.. Protective effects of brain infarction by N-acetylcysteine derivatives. Stroke. 2018, 49:1727-33. 10.1161\/STROKEAHA.118.021755","journal-title":"Stroke"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S241497","article-title":"Evidence for a beneficial effect of oral N-acetylcysteine on functional outcomes and inflammatory biomarkers in patients with acute ischemic stroke","volume":"16","author":"Sabetghadam M","year":"2020","unstructured":"Sabetghadam M, Mazdeh M, Abolfathi P, Mohammadi Y, Mehrpooya M. Evidence for a beneficial effect of oral N-acetylcysteine on functional outcomes and inflammatory biomarkers in patients with acute ischemic stroke. Neuropsychiatr Dis Treat. 2020, 16:1265-78. 10.2147\/NDT.S241497","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2469486","article-title":"N-acetylcysteine for the treatment of psychiatric disorders: a review of current evidence","volume":"2018","author":"Ooi SL","year":"2018","unstructured":"Ooi SL, Green R, Pak SC. N-acetylcysteine for the treatment of psychiatric disorders: a review of current evidence. Biomed Res Int. 2018, 2018:2469486. 10.1155\/2018\/2469486","journal-title":"Biomed Res Int"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-014-0142-x","article-title":"Potential role of N-acetylcysteine in the management of substance use disorders","volume":"28","author":"McClure EA","year":"2014","unstructured":"McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM. Potential role of N-acetylcysteine in the management of substance use disorders. CNS Drugs. 2014, 28:95-106. 10.1007\/s40263-014-0142-x","journal-title":"CNS Drugs"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2017.02.024","article-title":"N-acetylcysteine for treating cocaine addiction - a systematic review","volume":"251","author":"Nocito Echevarria MA","year":"2017","unstructured":"Nocito Echevarria MA, Andrade Reis T, Ruffo Capatti G, Siciliano Soares V, da Silveira DX, Fidalgo TM. N-acetylcysteine for treating cocaine addiction - a systematic review. Psychiatry Res. 2017, 251:197-203. 10.1016\/j.psychres.2017.02.024","journal-title":"Psychiatry Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2013.12034.x","article-title":"A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence","volume":"22","author":"LaRowe SD","year":"2013","unstructured":"LaRowe SD, Kalivas PW, Nicholas JS, Randall PK, Mardikian PN, Malcolm RJ. A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. Am J Addict. 2013, 22:443-52. 10.1111\/j.1521-0391.2013.12034.x","journal-title":"Am J Addict"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1503\/jpn.100057","article-title":"N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action","volume":"36","author":"Dean O","year":"2011","unstructured":"Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci. 2011, 36:78-86. 10.1503\/jpn.100057","journal-title":"J Psychiatry Neurosci"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-1173-2","article-title":"Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis","volume":"17","author":"Jakobsen JC","year":"2017","unstructured":"Jakobsen JC, Katakam KK, Schou A, et al.. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMC Psychiatry. 2017, 17:58. 10.1186\/s12888-016-1173-2","journal-title":"BMC Psychiatry"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s11126-013-9281-3","article-title":"N-Acetylcysteine and metabotropic glutamate receptors: implications for the treatment of schizophrenia: a literature review","volume":"85","author":"Zavodnick AD","year":"2014","unstructured":"Zavodnick AD, Ali R. N-Acetylcysteine and metabotropic glutamate receptors: implications for the treatment of schizophrenia: a literature review. Psychiatr Q. 2014, 85:177-85. 10.1007\/s11126-013-9281-3","journal-title":"Psychiatr Q"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029341","article-title":"Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial","volume":"7","author":"Carmeli C","year":"2012","unstructured":"Carmeli C, Knyazeva MG, Cu\u00e9nod M, Do KQ. Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial. PLoS One. 2012, 7:e29341. 10.1371\/journal.pone.0029341","journal-title":"PLoS One"},{"key":"ref38","article-title":"Placebo-controlled augmentation trials of the antioxidant NAC in schizophrenia: A review","volume":"28","author":"Chen AT","year":"2016","unstructured":"Chen AT, Chibnall JT, Nasrallah HA. Placebo-controlled augmentation trials of the antioxidant NAC in schizophrenia: A review. Ann Clin Psychiatry. 2016, 28:190-6.","journal-title":"Ann Clin Psychiatry"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12862","article-title":"N-acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials","volume":"137","author":"Zheng W","year":"2018","unstructured":"Zheng W, Zhang QE, Cai DB, et al.. N-acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials. Acta Psychiatr Scand. 2018, 137:391-400. 10.1111\/acps.12862","journal-title":"Acta Psychiatr Scand"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2011.02.011","article-title":"Nutraceuticals in the treatment of obsessive compulsive disorder (OCD): a review of mechanistic and clinical evidence","volume":"35","author":"Camfield DA","year":"2011","unstructured":"Camfield DA, Sarris J, Berk M. Nutraceuticals in the treatment of obsessive compulsive disorder (OCD): a review of mechanistic and clinical evidence. Prog Neuropsychopharmacol Biol Psychiatry. 2011, 35:887-95. 10.1016\/j.pnpbp.2011.02.011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2017.1251580","article-title":"N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects","volume":"13","author":"Minarini A","year":"2017","unstructured":"Minarini A, Ferrari S, Galletti M, Giambalvo N, Perrone D, Rioli G, Galeazzi GM. N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects. Expert Opin Drug Metab Toxicol. 2017, 13:279-92. 10.1080\/17425255.2017.1251580","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15r09984","article-title":"N-Acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis","volume":"77","author":"Fernandes BS","year":"2016","unstructured":"Fernandes BS, Dean OM, Dodd S, Malhi GS, Berk M. N-Acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis. J Clin Psychiatry. 2016, 77:e457-66. 10.4088\/JCP.15r09984","journal-title":"J Clin Psychiatry"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2008.04.022","article-title":"N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial","volume":"64","author":"Berk M","year":"2008","unstructured":"Berk M, Copolov DL, Dean O, et al.. N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008, 64:468-75. 10.1016\/j.biopsych.2008.04.022","journal-title":"Biol Psychiatry"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1177\/030006058301100505","article-title":"Acetylcysteine (Fabrol) in chronic bronchitis--a study in general practice","volume":"11","author":"Tattersall AB","year":"1983","unstructured":"Tattersall AB, Bridgman KM, Huitson A. Acetylcysteine (Fabrol) in chronic bronchitis--a study in general practice. J Int Med Res. 1983, 11:279-84. 10.1177\/030006058301100505","journal-title":"J Int Med Res"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.2000.16b12.x","article-title":"The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review","volume":"16","author":"Stey C","year":"2000","unstructured":"Stey C, Steurer J, Bachmann S, Medici TC, Tram\u00e8r MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J. 2000, 16:253-62. 10.1034\/j.1399-3003.2000.16b12.x","journal-title":"Eur Respir J"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1186\/2047-783x-14-8-352","article-title":"A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis","volume":"14","author":"Dauletbaev N","year":"2009","unstructured":"Dauletbaev N, Fischer P, Aulbach B, et al.. A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis. Eur J Med Res. 2009, 14:352-8. 10.1186\/2047-783x-14-8-352","journal-title":"Eur J Med Res"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0511304103","article-title":"High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis","volume":"103","author":"Tirouvanziam R","year":"2006","unstructured":"Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A. 2006, 103:4628-33. 10.1073\/pnas.0511304103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref48","article-title":"Effects of N-acetylcysteine on asthma exacerbation","author":"Aliyali","year":"2010","unstructured":"Aliyali, Amiri, Sharifpoor, et al.. Effects of N-acetylcysteine on asthma exacerbation. Iran J Allergy Asthma Immunol. 2010, 103-9.","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"ref49","article-title":"Preventive effect of N-acetylcysteine in a mouse model of steroid resistant acute exacerbation of asthma","volume":"12","author":"Eftekhari P","year":"2013","unstructured":"Eftekhari P, Hajizadeh S, Raoufy MR, et al.. Preventive effect of N-acetylcysteine in a mouse model of steroid resistant acute exacerbation of asthma. EXCLI J. 2013, 12:184-92.","journal-title":"EXCLI J"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1002\/alr.21145","article-title":"N-acetylcysteine exerts therapeutic action in a rat model of allergic rhinitis","volume":"3","author":"Guibas GV","year":"2013","unstructured":"Guibas GV, Spandou E, Meditskou S, Vyzantiadis TA, Priftis KN, Anogianakis G. N-acetylcysteine exerts therapeutic action in a rat model of allergic rhinitis. Int Forum Allergy Rhinol. 2013, 3:543-9. 10.1002\/alr.21145","journal-title":"Int Forum Allergy Rhinol"},{"key":"ref51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2008.12.170","article-title":"Topical N-acetyl cysteine (NAC) reduces late phase nasal symptoms following ragweed challenge","volume":"123","author":"Lane C","year":"2009","unstructured":"Lane C, Redding D, Gonzalez K, et al.. Topical N-acetyl cysteine (NAC) reduces late phase nasal symptoms following ragweed challenge. J Allergy Clin Immunol. 2009, 123:S53.","journal-title":"J Allergy Clin Immunol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042976","article-title":"High-dose acetylcysteine in idiopathic pulmonary fibrosis","volume":"353","author":"Demedts M","year":"2005","unstructured":"Demedts M, Behr J, Buhl R, et al.. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005, 353:2229-42. 10.1056\/NEJMoa042976","journal-title":"N Engl J Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-10-101","article-title":"Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial","volume":"10","author":"Behr J","year":"2009","unstructured":"Behr J, Demedts M, Buhl R, et al.. Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial. Respir Res. 2009, 10:101. 10.1186\/1465-9921-10-101","journal-title":"Respir Res"},{"key":"ref54","article-title":"Clinical use of evidence-based medicine--clinical questions: Acetylcysteine, a new treatment for an old foe?","volume":"105","author":"Bennett L","year":"2006","unstructured":"Bennett L, Crouse R, Feldstein D. Clinical use of evidence-based medicine--clinical questions: Acetylcysteine, a new treatment for an old foe?. WMJ. 2006, 105:6-7.","journal-title":"WMJ"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/s0891-5849(00)00215-x","article-title":"Regulation of redox glutathione levels and gene transcription in lung inflammation: therapeutic approaches","volume":"28","author":"Rahman I","year":"2000","unstructured":"Rahman I, MacNee W. Regulation of redox glutathione levels and gene transcription in lung inflammation: therapeutic approaches. Free Radic Biol Med. 2000, 28:1405-20. 10.1016\/s0891-5849(00)00215-x","journal-title":"Free Radic Biol Med"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2005.00725.x","article-title":"A pilot study of aerosolized N-acetylcysteine for idiopathic pulmonary fibrosis","volume":"10","author":"Tomioka H","year":"2005","unstructured":"Tomioka H, Kuwata Y, Imanaka K, et al.. A pilot study of aerosolized N-acetylcysteine for idiopathic pulmonary fibrosis. Respirology. 2005, 10:449-55. 10.1111\/j.1440-1843.2005.00725.x","journal-title":"Respirology"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198812153192401","article-title":"Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985)","volume":"319","author":"Smilkstein MJ","year":"1988","unstructured":"Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med. 1988, 319:1557-62. 10.1056\/NEJM198812153192401","journal-title":"N Engl J Med"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1056\/nejm197703032960914","article-title":"N-acetylcysteine for acetaminophen overdosage (cont.)","volume":"296","author":"Peterson RG","year":"1977","unstructured":"Peterson RG, Rumack BH. N-acetylcysteine for acetaminophen overdosage (cont.). N Engl J Med. 1977, 296:515. 10.1056\/nejm197703032960914","journal-title":"N Engl J Med"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/gov062","article-title":"Mycetismus: a review","volume":"4","author":"Smith MR","year":"2016","unstructured":"Smith MR, Davis RL. Mycetismus: a review. Gastroenterol Rep (Oxf). 2016, 4:107-12. 10.1093\/gastro\/gov062","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/s0750-7658(99)80127-0","article-title":"Massive paraquat poisoning. Favorable course after treatment with n-acetylcysteine and early hemodialysis [Article in French]","volume":"18","author":"Drault JN","year":"1999","unstructured":"Drault JN, Baelen E, Mehdaoui H, Delord JM, Flament F. Massive paraquat poisoning. Favorable course after treatment with n-acetylcysteine and early hemodialysis [Article in French]. Ann Fr Anesth Reanim. 1999, 18:534-7. 10.1016\/s0750-7658(99)80127-0","journal-title":"Ann Fr Anesth Reanim"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-010-0071-0","article-title":"Acute chloroform ingestion successfully treated with intravenously administered N-acetylcysteine","volume":"6","author":"Dell'Aglio DM","year":"2010","unstructured":"Dell'Aglio DM, Sutter ME, Schwartz MD, Koch DD, Algren DA, Morgan BW. Acute chloroform ingestion successfully treated with intravenously administered N-acetylcysteine. J Med Toxicol. 2010, 6:143-6. 10.1007\/s13181-010-0071-0","journal-title":"J Med Toxicol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2012.07.007","article-title":"N-acetylcysteine (NAC) diminishes the severity of PCB 126-induced fatty liver in male rodents","volume":"302","author":"Lai IK","year":"2012","unstructured":"Lai IK, Dhakal K, Gadupudi GS, Li M, Ludewig G, Robertson LW, Olivier AK. N-acetylcysteine (NAC) diminishes the severity of PCB 126-induced fatty liver in male rodents. Toxicology. 2012, 302:25-33. 10.1016\/j.tox.2012.07.007","journal-title":"Toxicology"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199106273242604","article-title":"Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure","volume":"324","author":"Harrison PM","year":"1991","unstructured":"Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med. 1991, 324:1852-7. 10.1056\/NEJM199106273242604","journal-title":"N Engl J Med"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.4103\/1319-3767.207711","article-title":"Role of N-acetylcysteine treatment in non-acetaminophen-induced acute liver failure: a prospective study","volume":"23","author":"Nabi T","year":"2017","unstructured":"Nabi T, Nabi S, Rafiq N, Shah A. Role of N-acetylcysteine treatment in non-acetaminophen-induced acute liver failure: a prospective study. Saudi J Gastroenterol. 2017, 23:169-75. 10.4103\/1319-3767.207711","journal-title":"Saudi J Gastroenterol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-009-9151-0","article-title":"Role of N-acetylcysteine in adults with non-acetaminophen-induced acute liver failure in a center without the facility of liver transplantation","volume":"3","author":"Mumtaz K","year":"2009","unstructured":"Mumtaz K, Azam Z, Hamid S, Abid S, Memon S, Ali Shah H, Jafri W. Role of N-acetylcysteine in adults with non-acetaminophen-induced acute liver failure in a center without the facility of liver transplantation. Hepatol Int. 2009, 3:563-70. 10.1007\/s12072-009-9151-0","journal-title":"Hepatol Int"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2015.01.003","article-title":"Efficacy and safety of acetylcysteine in \"non-acetaminophen\" acute liver failure: a meta-analysis of prospective clinical trials","volume":"39","author":"Hu J","year":"2015","unstructured":"Hu J, Zhang Q, Ren X, Sun Z, Quan Q. Efficacy and safety of acetylcysteine in \"non-acetaminophen\" acute liver failure: a meta-analysis of prospective clinical trials. Clin Res Hepatol Gastroenterol. 2015, 39:594-9. 10.1016\/j.clinre.2015.01.003","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2015.10.006","article-title":"Antioxidant therapy for treatment of inflammatory bowel disease: Does it work?","volume":"6","author":"Moura FA","year":"2015","unstructured":"Moura FA, de Andrade KQ, Dos Santos JC, Ara\u00fajo OR, Goulart MO. Antioxidant therapy for treatment of inflammatory bowel disease: Does it work?. Redox Biol. 2015, 6:617-39. 10.1016\/j.redox.2015.10.006","journal-title":"Redox Biol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2005.03.013","article-title":"N-acetyl-cysteine abolishes hydrogen peroxide-induced modification of eukaryotic initiation factor 4F activity via distinct signalling pathways","volume":"18","author":"O'Loghlen A","year":"2006","unstructured":"O'Loghlen A, P\u00e9rez-Morgado MI, Salinas M, Mart\u00edn ME. N-acetyl-cysteine abolishes hydrogen peroxide-induced modification of eukaryotic initiation factor 4F activity via distinct signalling pathways. Cell Signal. 2006, 18:21-31. 10.1016\/j.cellsig.2005.03.013","journal-title":"Cell Signal"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.00499","article-title":"Crohn\u2019s disease in clinical remission is marked by systemic oxidative stress","volume":"10","author":"Bourgonje AR","year":"2019","unstructured":"Bourgonje AR, von Martels JZ, Bulthuis ML, van Londen M, Faber KN, Dijkstra G, van Goor H. Crohn\u2019s disease in clinical remission is marked by systemic oxidative stress. Front Physiol. 2019, 10:499. 10.3389\/fphys.2019.00499","journal-title":"Front Physiol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2020.08.010","article-title":"Effect of N-acetylcysteine on remission maintenance in patients with ulcerative colitis: a randomized, double-blind controlled clinical trial","volume":"45","author":"Masnadi Shirazi K","year":"2021","unstructured":"Masnadi Shirazi K, Sotoudeh S, Masnadi Shirazi A, Moaddab SY, Nourpanah Z, Nikniaz Z. Effect of N-acetylcysteine on remission maintenance in patients with ulcerative colitis: a randomized, double-blind controlled clinical trial. Clin Res Hepatol Gastroenterol. 2021, 45:101532. 10.1016\/j.clinre.2020.08.010","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.080804","article-title":"Reactive oxygen species controls endometriosis progression","volume":"175","author":"Ng\u00f4 C","year":"2009","unstructured":"Ng\u00f4 C, Ch\u00e9reau C, Nicco C, Weill B, Chapron C, Batteux F. Reactive oxygen species controls endometriosis progression. Am J Pathol. 2009, 175:225-34. 10.2353\/ajpath.2009.080804","journal-title":"Am J Pathol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2006.05.003","article-title":"Antioxidant N-acetyl cysteine reduces incidence and multiplicity of lymphoma in Atm deficient mice","volume":"5","author":"Reliene R","year":"2006","unstructured":"Reliene R, Schiestl RH. Antioxidant N-acetyl cysteine reduces incidence and multiplicity of lymphoma in Atm deficient mice. DNA Repair (Amst). 2006, 5:852-9. 10.1016\/j.dnarep.2006.05.003","journal-title":"DNA Repair (Amst)"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/s0015-0282(16)57320-8","article-title":"Endometriosis and infertility: the role of exogenous lipid peroxides in the peritoneal fluid","volume":"63","author":"Arumugam K","year":"1995","unstructured":"Arumugam K, Dip YC. Endometriosis and infertility: the role of exogenous lipid peroxides in the peritoneal fluid. Fertil Steril. 1995, 63:198-9. 10.1016\/s0015-0282(16)57320-8","journal-title":"Fertil Steril"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1161\/01.res.0000046227.65158.f8","article-title":"Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis","volume":"91","author":"Ushio-Fukai M","year":"2002","unstructured":"Ushio-Fukai M, Tang Y, Fukai T, et al.. Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res. 2002, 91:1160-7. 10.1161\/01.res.0000046227.65158.f8","journal-title":"Circ Res"},{"key":"ref75","article-title":"Antiapoptotic and antigenotoxic effects of N-acetylcysteine in human cells of endothelial origin","volume":"20","author":"Aluigi MG","year":"2000","unstructured":"Aluigi MG, De Flora S, D'Agostini F, Albini A, Fassina G. Antiapoptotic and antigenotoxic effects of N-acetylcysteine in human cells of endothelial origin. Anticancer Res. 2000, 20:3183-7.","journal-title":"Anticancer Res"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.5.1967","article-title":"Glutathione deficiency is associated with impaired survival in HIV disease","volume":"94","author":"Herzenberg LA","year":"1997","unstructured":"Herzenberg LA, De Rosa SC, Dubs JG, et al.. Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci U S A. 1997, 94:1967-72. 10.1073\/pnas.94.5.1967","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345763","article-title":"Prolonged treatment with N-acetylcysteine and L-arginine restores gonadal function in patients with polycystic ovary syndrome","volume":"32","author":"Masha A","year":"2009","unstructured":"Masha A, Manieri C, Dinatale S, Bruno GA, Ghigo E, Martina V. Prolonged treatment with N-acetylcysteine and L-arginine restores gonadal function in patients with polycystic ovary syndrome. J Endocrinol Invest. 2009, 32:870-2. 10.1007\/BF03345763","journal-title":"J Endocrinol Invest"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2004.07.960","article-title":"N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate-resistant patients with polycystic ovary syndrome","volume":"83","author":"Rizk AY","year":"2005","unstructured":"Rizk AY, Bedaiwy MA, Al-Inany HG. N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate-resistant patients with polycystic ovary syndrome. Fertil Steril. 2005, 83:367-70. 10.1016\/j.fertnstert.2004.07.960","journal-title":"Fertil Steril"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1080\/00016340601090337","article-title":"N-Acetyl cysteine and clomiphene citrate for induction of ovulation in polycystic ovary syndrome: a cross-over trial","volume":"86","author":"Badawy A","year":"2007","unstructured":"Badawy A, State O, Abdelgawad S. N-Acetyl cysteine and clomiphene citrate for induction of ovulation in polycystic ovary syndrome: a cross-over trial. Acta Obstet Gynecol Scand. 2007, 86:218-22. 10.1080\/00016340601090337","journal-title":"Acta Obstet Gynecol Scand"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/311141-n-acetylcysteine-clinical-applications","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T07:59:57Z","timestamp":1729756797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/311141-n-acetylcysteine-clinical-applications"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":79,"URL":"https:\/\/doi.org\/10.7759\/cureus.72252","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,24]]}}}